Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari
event image
icon_therapy_area

Introducing ▼ REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.

Introducing REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.

Language Icon English
duration icon 27:15
Event topic Icon Antifungal, Rezzayo
Antifungal
Select Therapy Icon

Professor Tihana Bicanic Professor Oliver Cornely Professor Matteo Bassetti

Launch webinar introducing REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.1 Speakers Professor Tihana Bicanic, Professor Oliver Cornley and Matteo Bassetti present.

Professor Tihana Bicanic

Reader and Consultant in Infectious diseases at St George's University of London.

Upcoming Webinar

Introducing ▼ REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.


27:15

27:15

I'M INTERESTED
Professor Tihana Bicanic

Speaker

Professor Tihana Bicanic
Reader and Consultant in Infectious diseases at St George's University of London.
oliver

Speaker

Professor Oliver Cornely
Director & Chair of Translational Research at the CECAD Institute of the University of Cologne, and Scientific Director of the Center for Clinical Trials. Clinically, he serves as Infectious Diseases Consultant at the University Hospital of Cologne, Germany.
Professor Matteo Bassetti

Speaker

Professor Matteo Bassetti
Head of the Infectious Diseases Clinic of the Policlinico San Martino University Hospital in Genoa and Professor of Infectious Diseases of the University of Genoa, Italy.
Subscribe to Antifungal